Angelini Pharma secures US foothold with $4.1bn Catalyst
Italian pharmaceutical group Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals in an all-cash transaction valued at $4.1bn. The acquisition marks a pivotal expansion for the privately held European drugmaker, establishing its first direct commercial footprint in the United States while bolstering its central nervous system and rare disease portfolio. The transaction is expected to close in the third quarter…
Reale Mutua acquires majority stake in Lifenet Healthcare
Italian mutual insurer Reale Mutua has agreed to acquire an 80% stake in prominent hospital and outpatient services Lifenet Healthcare in a transaction valuing the company at approximately €600 million. The deal will see Reale Mutua, acting through its subsidiary Reale Services, purchase the majority equity interest from Exor, the investment arm of the Agnelli family, and Invin S.r.l., the…
Health Italia moves towards delisting
Health Italia, a prominent player in the Italian integrative healthcare and corporate welfare market, is moving toward a delisting from the Euronext Growth Milan. This transition follows the successful completion of a majority stake acquisition by Lonvita, a vehicle controlled by a club deal organised by promoters Giovanni Giuliani and Stefano Pellegrino. The transaction, which closed on December 5, 2025,…